APP and Alzheimer disease: Moreover, PF11 produced cognitive enhancing effects in both Aβ1-42-induced and Tg-APPswe/PS1dE9 (APP/PS1) mouse AD models and in 6-hydroxydopamine (6-OHDA)-induced Parkinson’s disease model [113, 114].